Home
    Disclaimer
    Fluclotizolam molecular structure

    Fluclotizolam Stats & Data

    NPS DataHub
    MW332.79
    FormulaC15H10ClFN4S
    IUPAC(2-Chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
    SMILESFc1ccccc1C1=NCc2nnc(C)n2c2sc(Cl)cc12
    InChIKeyZDYRCUZZLRLMHG-UHFFFAOYSA-N
    2020/3. Benzodiazepine; 2021/3. Benzodiazepine; 2022/3. Benzodiazepine
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant
    Half-Life Not well-characterized in humans; user reports suggest a short effective half-life with active sedation ~3–6 h and prolonged residual effects; metabolites not fully characterized.

    Receptor Profile

    Receptor Actions

    Modulators
    GABA-A receptor positive allosteric modulator (benzodiazepine site)

    History & Culture

    Fluclotizolam is a thienotriazolodiazepine that was originally synthesized in 1979 but was never developed for medical use or brought to market as a pharmaceutical product. The compound remained obscure for nearly four decades until it resurfaced as a designer drug in the mid-2010s. It was first definitively identified through analytical methods in 2017, joining the growing class of novel benzodiazepines appearing on the research chemical market.

    Effect Profile

    Curated + 1 Reports
    Benzodiazepine 8.0

    Strong anxiolysis and euphoria with mild sedation and cognitive impairment

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    4
    Euphoria / Mood Lift×1
    10

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Not well-characterized in humans; user reports suggest a short effective half-life with active sedation ~3–6 h and prolonged residual effects; metabolites not fully characterized.
    Addiction Potential
    High: short effective duration and high potency encourage redosing; tolerance and physical dependence can develop rapidly with repeated use.

    Tolerance Decay

    Full tolerance 5d Half tolerance 3d Baseline ~14d

    Rapid tolerance accumulation is typical with short-acting, high-potency benzos; intermittent spacing (≥2–3 weeks) best limits tolerance and withdrawal risk.

    Cross-Tolerances

    all benzodiazepines
    80% ●●○
    z-drugs
    50% ●○○

    Experience Report Analysis

    Erowid
    1 Reports
    2017–2017 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Harm Reduction

    drugs.wiki

    Potency varies by batch; start with no more than 0.1–0.25 mg and wait 2+ hours before considering any redose. Sub-milligram accuracy is essential—use volumetric dosing (e.g., 1 mg in 10 mL 50:50 ethanol:water or PG/ethanol) measured with a marked oral syringe; do not rely on drop counts due to large variability. Most benzodiazepines are poorly water-soluble and perform unpredictably intranasally; oral or sublingual routes are safer and more consistent. New benzodiazepines are frequently mis-sold or adulterated; counterfeit 'benzo' tablets and liquids have been found to contain bromazolam, stimulants, and even nitazene opioids—use an accredited drug checking service where available. Combining with opioids or other depressants is the primary cause of fatal outcomes; avoid co-use, and ensure naloxone and oxygen access if opioids are present. Short-acting, high-potency benzos increase blackout and 'delusions of sobriety'; set a hard cap (≤0.5 mg per 12 h) and avoid daily use. Expect rebound insomnia/anxiety as effects wear off; spacing uses by weeks reduces tolerance and withdrawal risk. Standard immunoassay urine tests target oxazepam-like metabolites and may miss some designer benzos; specialized confirmatory testing is needed. Avoid driving or hazardous tasks for at least 8–12 h after the last dose, longer if drowsy.

    ← Back to Fluclotizolam